<DOC>
	<DOCNO>NCT01171729</DOCNO>
	<brief_summary>This open label , Phase I/IIa trial immunotherapy CreaVax-PC treatment men hormone-Refractory Metastatic Prostate Cancer .</brief_summary>
	<brief_title>Autologous Dendritic Cell Therapy Hormone-Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>CreaVax-PC consist antigen ( PSA , PAP KLH ) prim dendritic cell investigational product design activate man 's immune response , detect prostate cancer cell initiate immune response prostate cancer antigen . If patient decide participate eligible , enrol study receive active product ( CreaVax-PC ) . In detail , patient receive CreaVax-PC injection interval 3 week , maximum 6 time 21 week . PSA increase rate primary evaluation variable tumor suppression effect secondary evaluation variable . We also evaluate time progression , overall survival immune response .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 ) Histological confirm prostatic carcinoma patient 2 ) Hormone nonrespondence ex1 ) Although treatment PSA ≥ 5ng/ml ex2 ) PSA level measure two time ex3 ) Prior one year radiology process 3 ) Just 18 year 4 ) Has score ≤1 ECOG Performance Scale 5 ) Expected survival life time ≥ 6month 6 ) Adequate bone marrow function hemoglobin ≥ 10.0g/dL , leukocyte count ≥ 4,000/mm3 thrombocyte ≥ 100,000/mm3 7 ) Adequate blood coagulation function PT ( INR ) &lt; 1.5 , aPTT &lt; 1.5 x control 8 ) Adequate kidney function Normal blood upper level Creatinine ≤ 1.5 time 9 ) Adequate liver function Normal blood upper level AST/ALT ≤ 1.5 time 10 ) Autoimmune antibody system n't disorder ex ) antinuclear antibody , antithyroglobulin antibody negativity 11 ) Person n't treat prior 6 week operation , radiotherapy treatment , immunotherapy chemotherapy 12 ) Patient voluntarily participate clinical trial confirm write consent 1 ) Having malignancy previous history malignancy 2 ) Brain metastasis patient 3 ) Having autoimmune disease history 4 ) Pyrexia , rigor , leukocytosis infectious disease 5 ) HBsAg , antiHCV , HIV positive patient 6 ) Myocardial infarction , cardiac insufficiency , severe heart disease noncontrolled hypertension 7 ) Severe active medical disease 8 ) Mental history disease epilepsy 9 ) Patients participate clinical trial within 4 week 10 ) Patients impossible participate trial investigator 's decision 11 ) Patients receive immunosuppressant steroid , cyclosporin A , azathioprine within 6 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>PSA</keyword>
	<keyword>Hormone refractory prostatic cancer</keyword>
</DOC>